NICE has approved Allergan’s Truberzi for treatment of irritable bowel syndrome.
Truberzi binds receptors in the digestive system to relieve stomach cramps. The drug will be available for patients who are non-responsive to other treatments. It will be made available in addition to existing drug and psychological treatments for the condition, according to Professor Carole Longson, director of the center for health technology evaluation at NICE.
The agency recommends the drug only for secondary care and calls for stopping the treatment after four weeks if it fails to relieve symptoms.